Trial Profile
Randomized Open-Label Neo-Adjuvant Phase II Study Comparing Ixabepilone (I) Vs. Ixabepilone Plus Cetuximab (IC) in Triple Negative Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Ixabepilone (Primary)
- Indications Adenocarcinoma; Carcinoma; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 13 May 2020 Status changed from active, no longer recruiting to completed.
- 23 Jul 2018 Planned End Date changed from 1 Dec 2016 to 1 Dec 2019.
- 23 Jul 2018 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2019.